منابع مشابه
Current treatment of soft tissue sarcoma.
arcomas are rare tumors, representing only 0.8% of new cancers in the United States. Seventy-six percent arise in soft tissue, with the remainder arising in bone (1). The most common soft tissue type is malignant fibrous histiosarcoma, although this has fallen out of favor recently as a distinct histologic entity (2, 3). Multiple types of soft tissue sarcomas are defined based on the tissue of ...
متن کاملSoft Tissue Sarcoma – Current Management
Progress has been made • The understanding of the biology (cytoand molecular genetics) of the tumour has improved. The identification of the translocation in alveolar RMS has been important, particularly in the identification of those patients who have tumours with a poorer outlook. The t(2;13) and t(1:13) are known to be associated with alveolar disease the former carrying the poorer prognosis...
متن کاملSynovial Sarcoma of the Head and Neck: A Case of Childhood Soft Tissue Sarcoma
Although rare, synovial sarcoma is the most common malignant non-rhabdomyosarcomatous soft tissue sarcoma in children and adolescents. Synovial sarcoma typically involves the soft tissues of the extremities, especially near large joints, but it can occur anywhere in the body in locations far from joint spaces. Although this tumor typically affects adults in their fourth decade of life, nearly h...
متن کاملAdjuvant Chemotherapy of Soft Tissue Sarcoma—Current Status
It is acknowledged that, although improvements can be made in local control, e.g. by the use of adjuvant radiotherapy, the major challenge in the management of adult soft tissue sarcomas is the treatment of distant metastatic disease.We lack very effective drugs capable of providing long-term disease control once this event has occurred. Palliation is possible with doxorubicin, ifosfamide or co...
متن کاملTrabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives
UNLABELLED Trabectedin (ET743, Yondelis(®), manufactured by Baxter Oncology GmbH, Halle/Westfalen, Germany, for Janssen Products, LP, Horsham, PA), derived from the marine ascidian, Ecteinascidia turbinata, is a natural alkaloid with multiple complex mechanisms of action. On 23 October 2015, 15 years after the results of the first Phase 1 clinical trial using trabectedin for chemotherapy-resist...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Baylor University Medical Center Proceedings
سال: 2008
ISSN: 0899-8280,1525-3252
DOI: 10.1080/08998280.2008.11928435